Targeted therapies in hematology and their impact on patient care: Chronic and acute myeloid leukemia

Elias Jabbour, Jorge Cortes, Farhad Ravandi, Susan O'Brien, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Advances in the genetic and molecular characterizations of leukemias have enhanced our capabilities to develop targeted therapies. The most dramatic example of targeted therapy in cancer to date is the use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI), which has revolutionized the treatment of chronic myeloid leukemia (CML). Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. In contrast, acute myeloid leukemia (AML) is an extremely heterogeneous disease with outcomes that vary widely according to subtype of the disease. Targeted therapy with monoclonal antibodies and small molecule kinase inhibitors are promising strategies to help improve the cure rates in AML. In this review, we will highlight the results of recent clinical trials in which outcomes of CML and AML have been influenced significantly. Also, novel approaches to sequencing and combining available therapies will be covered.

Original languageEnglish (US)
Pages (from-to)271-283
Number of pages13
JournalSeminars in Hematology
Volume50
Issue number4
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Hematology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Patient Care
Phosphotransferases
Therapeutics
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Molecular Biology
Leukemia
Monoclonal Antibodies
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Targeted therapies in hematology and their impact on patient care : Chronic and acute myeloid leukemia. / Jabbour, Elias; Cortes, Jorge; Ravandi, Farhad; O'Brien, Susan; Kantarjian, Hagop.

In: Seminars in Hematology, Vol. 50, No. 4, 01.10.2013, p. 271-283.

Research output: Contribution to journalArticle

Jabbour, Elias ; Cortes, Jorge ; Ravandi, Farhad ; O'Brien, Susan ; Kantarjian, Hagop. / Targeted therapies in hematology and their impact on patient care : Chronic and acute myeloid leukemia. In: Seminars in Hematology. 2013 ; Vol. 50, No. 4. pp. 271-283.
@article{95b112f7d7fa468f8cc3317d18c4c7ad,
title = "Targeted therapies in hematology and their impact on patient care: Chronic and acute myeloid leukemia",
abstract = "Advances in the genetic and molecular characterizations of leukemias have enhanced our capabilities to develop targeted therapies. The most dramatic example of targeted therapy in cancer to date is the use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI), which has revolutionized the treatment of chronic myeloid leukemia (CML). Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. In contrast, acute myeloid leukemia (AML) is an extremely heterogeneous disease with outcomes that vary widely according to subtype of the disease. Targeted therapy with monoclonal antibodies and small molecule kinase inhibitors are promising strategies to help improve the cure rates in AML. In this review, we will highlight the results of recent clinical trials in which outcomes of CML and AML have been influenced significantly. Also, novel approaches to sequencing and combining available therapies will be covered.",
author = "Elias Jabbour and Jorge Cortes and Farhad Ravandi and Susan O'Brien and Hagop Kantarjian",
year = "2013",
month = "10",
day = "1",
doi = "10.1053/j.seminhematol.2013.09.006",
language = "English (US)",
volume = "50",
pages = "271--283",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeted therapies in hematology and their impact on patient care

T2 - Chronic and acute myeloid leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - O'Brien, Susan

AU - Kantarjian, Hagop

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Advances in the genetic and molecular characterizations of leukemias have enhanced our capabilities to develop targeted therapies. The most dramatic example of targeted therapy in cancer to date is the use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI), which has revolutionized the treatment of chronic myeloid leukemia (CML). Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. In contrast, acute myeloid leukemia (AML) is an extremely heterogeneous disease with outcomes that vary widely according to subtype of the disease. Targeted therapy with monoclonal antibodies and small molecule kinase inhibitors are promising strategies to help improve the cure rates in AML. In this review, we will highlight the results of recent clinical trials in which outcomes of CML and AML have been influenced significantly. Also, novel approaches to sequencing and combining available therapies will be covered.

AB - Advances in the genetic and molecular characterizations of leukemias have enhanced our capabilities to develop targeted therapies. The most dramatic example of targeted therapy in cancer to date is the use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI), which has revolutionized the treatment of chronic myeloid leukemia (CML). Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. In contrast, acute myeloid leukemia (AML) is an extremely heterogeneous disease with outcomes that vary widely according to subtype of the disease. Targeted therapy with monoclonal antibodies and small molecule kinase inhibitors are promising strategies to help improve the cure rates in AML. In this review, we will highlight the results of recent clinical trials in which outcomes of CML and AML have been influenced significantly. Also, novel approaches to sequencing and combining available therapies will be covered.

UR - http://www.scopus.com/inward/record.url?scp=84887511479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887511479&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2013.09.006

DO - 10.1053/j.seminhematol.2013.09.006

M3 - Article

C2 - 24246694

AN - SCOPUS:84887511479

VL - 50

SP - 271

EP - 283

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4

ER -